linjc16/ctgov huggingface dataset:
Transdermal Testosterone for Poor Responder Patients Undergoing Controlled Ovarian Stimulation Prior to IVF

Study Overview
=================
Brief Summary
-----------------
This study evaluates the efficacy of pre- IVF treatment with transdermal testosterone to enhance ovarian response in poor responders. a randomized controlled trial with two groups, treatment group with transdermal testosterone before IVF treatment and a control group with no treatment.

Detailed Description
-----------------
One of the major challenges of Assisted reproduction technology is treating women with low ovarian response,those women achieve very poor pregnancy rate with IVF. in recent years there is a focus

Official Title
-----------------
Transdermal Testosterone for Poor Responders Undergoing IVF

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Drug: Testosterone gel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infertility patients undergoing ART regular menses normal function of thyroid, liver and kidney normal BMI (19.3-28.9) without use of any fertility drugs in the previous two months Exclusion Criteria: patients with recurrent implantations failure (3 cycles and more) previous ovarian surgery uncontrolled medical illness severe endometriosis (stage 3-4) contraindication for testosterone use

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 42 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: testosterone gel<br>testosterone gel treatment group | Drug: Testosterone gel<br>* treatment with testosterone gel<br>* Other names: testomax;|
| No Intervention: Control group<br>without testosterone treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of retrieved oocytes | number of oocytes | 2 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of clinical pregnancies | number of pregnancies with fetal cardiac activity | 2.5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Poor responders
Preventing Cognitive Decline With Alternative Therapies

Study Overview
=================
Brief Summary
-----------------
Preventing dementia is an important goal for our aging population. This proposal is an initial 42 months study of the effect of standardized ginkgo biloba extract (GBE) on preventing or delaying cognitive decline in people age 85 years or older (the oldest old). The study focuses on the oldest old who present a distinct advantage for primary prevention studies because of their particularly high risk for developing mild cognitive impairment (MCI), a precursor to dementia. Because this is a population that has previously been out of the mainstream for use of alternative medicine, the safety of GBE in this age group will also be tested in this study. The study is randomized, placebo controlled and double blind. Approximately 200 elderly cognitively healthy subjects will be enrolled and followed for detection of conversion to MCI. This pilot study is viewed as a necessary first step in order to demonstrate that GBE, an alternative or complementary therapy, has a disease modifying effect on the brain, distinct from a symptomatic effect. The study will test the feasibility of the randomized start design, a trial design proposed as a method for discerning brain- or disease- modifying from symptomatic effects. The magnitude of biological effect of the treatments will also be assessed with volumetric quantitative MRI, a complementary means of confirming whether there is a brain modifying effect (measured as a decrease in brain volume loss with treatment). Peripheral markers of oxidation status will measure possible anti-oxidant effects of GBE.

Detailed Description
-----------------
See brief summary

Official Title
-----------------
Preventing Cognitive Decline With Alternative Therapies

Conditions
-----------------
Dementia, Memory Disorders

Intervention / Treatment
-----------------
* Drug: Ginkgo Biloba Extract


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Can identify a collateral informant who has frequent contact with the subject No memory complaints compared to others of same age group and has not sought attention for concerns about memory or cognition Normal memory function defined by an education-adjusted score on the Logical Memory Subscale of the Wechsler Memory Scale-Revised Mini-Mental State Examination Score >23 Clinical Dementia Rating (CDR) of zero

Ages Eligible for Study
-----------------
Minimum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ginkgo Biloba Extract|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Influence of Extracorporeal Circulation on Platelet Function of Patients Undergoing Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
This study is planned to investigate the relationship between duration of extracorporeal circulation and the extent of (acquired) platelet dysfunctions in patients undergoing cardiac surgery.

Detailed Description
-----------------
Patients undergoing complex cardiac surgery are planned to be included. At several intra- and postoperative measuring point, blood is drawn for multiple electrode aggregometry to investigate ex-vivo platelet aggregation as a surrogate for platelet function. Transfusion rate of allogenic blood products as well as postoperative blood loss is planned to be recorded.

Official Title
-----------------
Influence of Extracorporeal Circulation on Platelet Function of Patients Undergoing Cardiac Surgery - a Prospective Observational Study

Conditions
-----------------
Acquired Platelet Function Disorder

Intervention / Treatment
-----------------
* Device: Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: duration of extracorporeal circulation > 120 min Exclusion Criteria: pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cardiac surgery patients<br>cardiac surgery patients scheduled for elective complex cardiac surgery | Device: Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)<br>* ex vivo platelet aggregation at several intraoperative and postoperative measuring points.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in arachidonic acid induced platelet aggregation as compared to baseline (before extracorporeal circulation) | Multiple Electrode aggregometry parameters | Baseline (before extracorporeal circulation) and 60, 90, 120, 150 and 180 minutes after extracorporal circulation as well as ad admission to ICU | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Adenosin Diphosphate (ADP) and Thrombin induced platelet aggregation as compared to baseline (before extracorporeal circulation) | Multiple electrode aggregometry analyses | Baseline (before extracorporeal circulation) and 60, 90, 120, 150 and 180 minutes after extracorporal circulation as well as ad admission to ICU | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
extracorporeal circulation, platelet dysfunction, Multiplate electrode aggregometry analyses, Multiplate
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any possible long-term adverse consequences of increased iris pigmentation and to follow serious adverse events throughout the study period.

Official Title
-----------------
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

Conditions
-----------------
Glaucoma, Open-Angle, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Xalacom


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with open angle glaucoma and/or ocular hypertension requiring a reduction of IOP who were insufficiently responsive to topical betablockers Exclusion Criteria: Previous and current treatment with any topical ophthalmic drug containing prostaglandins; any condition in which treatment with the betablocking agent, timolol, was contraindicated.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Xalacom|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of increase of iris pigmentation |  |  | 
| incidence of development in darkening/lengthening/thickening of eyelashes and/or pigmentation of periorbital skin |  |  | 
| occurrence of ocular/periorbital adverse events |  |  | 
| occurrence of serious adverse events. |  |  |
Safety and Efficacy of Sufentanil Combined With Midazolam in Bronchoscopy Under Conscious Sedation: Retrospective Study

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to determine the safety and efficacy of sufentanil combined with midazolam in bronchoscopy under conscious sedation. A retrospective analysis was conducted on all patients undergoing bronchoscopy applying sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017.

Official Title
-----------------
Safety and Efficacy of Sufentanil Combined With Midazolam in Bronchoscopy Under Conscious Sedation: Retrospective Study

Conditions
-----------------
Bronchoscopy, Sedation

Intervention / Treatment
-----------------
* Drug: Sufentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 Exclusion Criteria: Patients who had undergone bronchoscopy not applying topical lidocaine, sufentanil and midazolam under conscious sedation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sufentanil and Midazolam<br>Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study. | Drug: Sufentanil<br>* Patients were applied sufentanil and midazolam intravenously and topical anesthetized.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygen desaturation | Percentage of patients whose oxygen saturation decreased to lower than 80% during procedure | during the procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sufentanil, Bronchoscopy, Conscious sedation, midazolam
ADHEPTA Study: Adherence Questionnaire in Hepatitis C

Study Overview
=================
Brief Summary
-----------------
Main objective: To study and validate a questionnaire measuring treatment adherence in patients with Hepatitis C virus (HCV) infection. Design of the study: Multicentric, prospective, epidemiological study in the field of usual clinical practice.

Official Title
-----------------
Development and Validation of a Questionnaire Measuring Treatment Adherence in Patients With Hepatitis C

Conditions
-----------------
Hepatitis C, Chronic, HIV Infection

Intervention / Treatment
-----------------
* Other: Adherence questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ambulatory patient infected by HCV according to diagnosis criteria used en usual clinical practice. Patient no treated previously and beginning a treatment for HCV. Patient that signed the informed consent to participate in the study. Group A: patient with HCV monoinfection. Group B: patient with HCV and HCV co-infection (according to diagnosis criteria used en usual clinical practice). Exclusion Criteria: Patient that received previous treatment for HCV. Patient that is going to participate in a clinical trial Turing the HCV treatment period. Patient with cognitive impairment or patient unable to understand and answer the auto-administered questionnaire. Patient unable to read or write Spanish.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hepatitis C infection<br> | Other: Adherence questionnaire<br>* Adherence questionnaire<br>|
| Hepatitis C + HIV infections<br> | Other: Adherence questionnaire<br>* Adherence questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Main objective of the study is the development and validation of a Questionnaire measuring treatment adherence in patients with HCV infection. |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence will be measured according to 80/80/80 rule. |  | 2 years | 
| Establish a relationship between adherence, virological response (VR) and Sustained virological response (SVR). |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis C, Chronic, HIV Infection, Medication Adherence, Questionnaire Design, Treatment experienced
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).

Detailed Description
-----------------
At entry, patients undergo HIV genotypic/phenotypic analysis. Patients continue their current antiretroviral regimen but are randomized to receive one of four doses of PEG-IFN or PEG-IFN placebo administered subcutaneously once per week until results of HIV genotyping/phenotyping are available (approximately 4 weeks). Patients who respond with a 0.5 log or greater decrease in HIV RNA at Week 4 have optimized HAART added to their ongoing PEG-IFN regimen and are followed for 24 weeks in an observational study.

Official Title
-----------------
Antiviral Activity and Tolerability of PEG-Intron in HIV-Infected Subjects Failing HAART

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Peginterferon alfa-2b


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients may be eligible for this study if they: Have HIV levels of more than 2000 copies/ml. Have failed their current HAART (had a significant increase in their HIV levels with HAART). Have a CD4 cell count greater than 200 cells/microL. Have had more than 6 months of HAART. Have been on their current HAART for at least 6 weeks. Agree to use an effective method of birth control during the study. Exclusion Criteria Patients will not be eligible for this study if they: Have a history of a serious mental disorder. Are allergic to interferons. Are pregnant or breast-feeding. Are taking certain medications such as ribavirin, hydroxyurea, and ganciclovir.

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Peginterferon alfa-2b|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Interferon Alfa-2b, Lymphocyte Transformation, CD4 Lymphocyte Count, RNA, Viral, Virus Inhibitors, Anti-HIV Agents, Viral Load
Does Block Play Improve Language Acquisition: A Randomized Trial

Study Overview
=================
Brief Summary
-----------------
This is a randomized controlled trial of distributing blocks to children ages 1.5 -2.5 years of age to see if language acquisition improves.

Detailed Description
-----------------
Children in age group are randomized to get two sets of blocks or not. Outcomes include language development assessed using the Macarthur Bates CDI 6 months after enrollment.

Official Title
-----------------
Clinical Trial of Building Block Distribution in Children

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: Building Blocks


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy children Exclusion Criteria: developmental delay, non-English

Ages Eligible for Study
-----------------
Minimum Age: 18 Months
Maximum Age: 30 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Building Blocks|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macarthur Bates Language Inventory |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TV viewing |  |  | 
| Block play |  |  |
Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Human Urinary Outflow Tract

Study Overview
=================
Brief Summary
-----------------
The aim is to find out if adreno-muscarinic synergy is present also in human tissues of the urinary outflow tract that have a dual adrenergic-muscarinic receptor fitting. To further characterise morphology and function of the suburothelial myofibroblast network in the human bladder outlet.

Official Title
-----------------
Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Continent and Incontinent Human Urinary Outflow Tract

Conditions
-----------------
Incontinence, Overactive Bladder, Stress Urinary Incontinence

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tissue will be collected from the operation theatre only after having obtained the patient´s consent and in strictest accordance with histopathological requirements, i.e. after assessment of resection margins. It might be necessary to retrieve the tissue from the pathologist after first pathological assessment is completed. Tissue will be placed in Tyrode´s solution, gassed with 95 % O2 and 5 % CO2, for functional and RT-PCR or Western blot experiments, or in OCT (optimal cutting temperature) compound, snap-frozen in liquid nitrogen, and stored in a -80°C freezer until cutting for immunohistochemical experiments. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |